Tango Therapeutics
TNGX----
Q1 FY2026 Earnings
Financial report interval: 2025.12.31 - 2026.03.31
Preview: Tango Therapeutics(TNGX) predict that the EBIT is -48.77 M (-14.67%), Miss estimate;the EPS is -0.32 (+11.11%), Miss estimate.
Actual
YoY
Estimate
YoY
Vs estimate
YoY
Revenue
TBA--
0.00B89.28%
----
EBITMiss expectations
-0.05B14.67%
-0.04B5.38%
-0.00B9.29%
EPSMiss expectations
-0.3211.11%
-0.314212.73%
-0.00581.62%
Revenue
ActualEstimateUnit: USD
qf
EBIT
ActualEstimateUnit: USD
qf
Net income
ActualEstimateUnit: USD
qf
EPS
ActualEstimateUnit: USD
qf